非典型糖尿病:我们学到了什么,未来又将如何?
本综述指出,许多糖尿病患者的表型不能简单归为1型或2型糖尿病,这些「非典型糖尿病」的研究促进了对胰岛素分泌、胰岛素抵抗和胰岛自身免疫基本生物学的理解。文章总结了已知非典型糖尿病类型的生物学与临床洞见,并基于临床、代谢和分子特征提出了识别此类患者的框架,同时提供了评估疑似患者可用的临床与遗传资源。
要点
- 许多糖尿病患者不能简单归类为1型或2型糖尿病。
- 非典型糖尿病研究加深了对胰岛素分泌、胰岛素抵抗和胰岛自身免疫的理解。
- 基于临床、代谢和分子特征可识别非典型糖尿病,并有助于靶向治疗决策。
核心结论
- 认识与非典型糖尿病相关的各种内型将提高诊断准确性并促进靶向治疗决策。
研究设计与样本
- 综述,总结了已知非典型糖尿病类型的生物学与临床洞见,并提供了基于临床、代谢和分子特征的识别框架以及评估疑似患者可用的临床与遗传资源。
主要发现
- 许多患者可能患有不能简单归为1型或2型糖尿病的糖尿病形式。
- 非典型糖尿病的发现和描述极大地促进了对驱动胰岛素分泌、胰岛素抵抗和胰岛自身免疫的基本生物学的集体理解。
- 这些发现为基于不同内型对糖尿病进行更好分类铺平了道路。
关键数值与推荐
- 提供了基于临床、代谢和分子特征识别非典型糖尿病患者的框架。
- 提供了评估疑似非典型糖尿病患者的临床和遗传资源。
临床怎么用
- 欣赏与非典型糖尿病相关的各种内型将提高诊断准确性并促进靶向治疗决策。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
As our understanding of the pathophysiology of diabetes evolves, we increasingly recognize that many patients may have a form of diabetes that does not neatly fit with a diagnosis of either type 1 or type 2 diabetes. The discovery and description of these forms of "atypical diabetes" have led to major contributions to our collective understanding of the basic biology that drives insulin secretion, insulin resistance, and islet autoimmunity. These discoveries now pave the way to a better classification of diabetes based on distinct endotypes. In this review, we highlight the key biological and clinical insights that can be gained from studying known forms of atypical diabetes. Additionally, we provide a framework for identification of patients with atypical diabetes based on their clinical, metabolic, and molecular features. Helpful clinical and genetic resources for evaluating patients suspected of having atypical diabetes are provided. Therefore, appreciating the various endotypes associated with atypical diabetes will enhance diagnostic accuracy and facilitate targeted treatment decisions.
引用
- Stone SI, Balasubramanyam A, Posey JE, et al. Atypical Diabetes: What Have We Learned and What Does the Future Hold? Diabetes Care. 2024. PMID: 38329838. doi:10.2337/dci23-0038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。